S Huang, P Huang, Z Lin, X Liu, X Xu, L Guo… - Experimental Eye …, 2018 - Elsevier
Glaucoma is a group of neurodegenerative eye diseases characterized by progressive impairment of visual function due to loss of retinal ganglion cells (RGC). As hydrogen sulfide …
P Raman, NB Suliman, M Zahari, M Kook, N Ramli - Eye, 2018 - nature.com
Objective To assess the relationship between baseline intraocular pressure (IOP), blood pressure (BP) and ocular perfusion pressure (OPP), and the 5-year visual field progression …
K Gillmann, A Aref, LJ Niegowski… - International …, 2021 - Springer
Purpose The aim of this study was to analyse the safety profile and efficacy of ab interno viscocanaloplasty (ABiC) through to 12 months post-operatively. Methods In this …
S Huang, P Huang, H Yu, J Chen, X Liu, J Wang… - Cell and Tissue …, 2022 - Springer
Glaucoma is a neurodegenerative disease of visual system characterized by gradual loss of retinal ganglion cells (RGC). Since mitochondrial dysfunction of RGC is significantly …
K Yoshikawa, K Santo, H Hizaki… - Clinical …, 2018 - Taylor & Francis
Purpose To analyze factors related to long-term progression of visual field defects (VFD) in patients with normal tension glaucoma (NTG) under medical therapy. Patients and methods …
WW Su, SS Hsieh, ST Cheng, CW Su… - Journal of …, 2018 - Wiley Online Library
Purpose. To investigate visual field progression pattern and factors associated with progression in patients with primary open‐angle glaucoma (POAG), normal‐tension …
T Yamamoto - Japanese Journal of Ophthalmology, 2019 - Springer
Purpose of review To trace the influence of disc hemorrhage studies on our understanding of glaucoma. Sources Major articles published during the last 50 years since the rediscovery …
JC Mwanza, SE Tulenko, DL Budenz… - Journal of …, 2022 - journals.lww.com
Purpose: To report the incidence of glaucoma progression and the rate of visual field deterioration in a small cohort of Ghanaians. Methods: One hundred ten subjects (204 eyes) …
K Yoshikawa, S Mizoue, K Nitta, H Onishi… - Clinical …, 2021 - Taylor & Francis
Purpose We previously investigated the efficacy and safety of adding 0.1% brimonidine (Brim) or 0.5% timolol (Tim) to prostaglandin analogue (PGA) monotherapy to treat patients …